Does the media favor CRSP or INBX?

In the previous week, Inhibrx Biosciences had 5 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 8 mentions for Inhibrx Biosciences and 3 mentions for CRISPR Therapeutics. CRISPR Therapeutics' average media sentiment score of 1.31 beat Inhibrx Biosciences' score of 0.08 indicating that CRISPR Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inhibrx Biosciences 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to INBX or ACAD?

In the previous week, ACADIA Pharmaceuticals had 9 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 17 mentions for ACADIA Pharmaceuticals and 8 mentions for Inhibrx Biosciences. ACADIA Pharmaceuticals' average media sentiment score of 0.94 beat Inhibrx Biosciences' score of 0.08 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inhibrx Biosciences 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral ACADIA Pharmaceuticals 7 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is INBX or DYN more profitable?

Dyne Therapeutics' return on equity of -64.30% beat Inhibrx Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Inhibrx Biosciences N/A -1,742.66% -81.62% Dyne Therapeutics N/A -64.30% -50.33%

Does the media favor INBX or DYN?

In the previous week, Inhibrx Biosciences had 6 more articles in the media than Dyne Therapeutics. MarketBeat recorded 8 mentions for Inhibrx Biosciences and 2 mentions for Dyne Therapeutics. Dyne Therapeutics' average media sentiment score of 1.03 beat Inhibrx Biosciences' score of 0.08 indicating that Dyne Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inhibrx Biosciences 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Dyne Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is INBX or CELC more profitable?

Celcuity's return on equity of -250.68% beat Inhibrx Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Inhibrx Biosciences N/A -1,742.66% -81.62% Celcuity N/A -250.68% -50.23%

Does the media favor INBX or CELC?

In the previous week, Celcuity had 14 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 22 mentions for Celcuity and 8 mentions for Inhibrx Biosciences. Celcuity's average media sentiment score of 0.47 beat Inhibrx Biosciences' score of 0.08 indicating that Celcuity is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inhibrx Biosciences 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Celcuity 7 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Is RLAY or INBX more profitable?

Relay Therapeutics' return on equity of -42.27% beat Inhibrx Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Relay Therapeutics N/A -42.27% -38.67% Inhibrx Biosciences N/A -1,742.66% -81.62%

Does the media refer more to RLAY or INBX?

In the previous week, Relay Therapeutics had 2 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 10 mentions for Relay Therapeutics and 8 mentions for Inhibrx Biosciences. Relay Therapeutics' average media sentiment score of 0.75 beat Inhibrx Biosciences' score of 0.08 indicating that Relay Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relay Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Inhibrx Biosciences 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Inhibrx Biosciences (INBX) Competitors

$88.37 -8.64 (-8.91%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$88.15 -0.22 (-0.25%)

As of 08/14/2026 07:34 PM Eastern

Compare

INBX vs. CRSP, ACAD, DYN, CELC, and RLAY

Should you buy Inhibrx Biosciences stock or one of its competitors? Inhibrx Biosciences's main competitors and comparable companies include CRISPR Therapeutics (CRSP), ACADIA Pharmaceuticals (ACAD), Dyne Therapeutics (DYN), Celcuity (CELC), and Relay Therapeutics (RLAY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Inhibrx Biosciences compare to CRISPR Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and Inhibrx Biosciences (NASDAQ:INBX) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk and earnings.

Inhibrx Biosciences has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -3,368.72%. CRISPR Therapeutics' return on equity of -24.39% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-3,368.72%	-24.39%	-18.25%
Inhibrx Biosciences	N/A	-1,742.66%	-81.62%

69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 82.5% of Inhibrx Biosciences shares are held by institutional investors. 5.2% of CRISPR Therapeutics shares are held by company insiders. Comparatively, 18.3% of Inhibrx Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Inhibrx Biosciences has lower revenue, but higher earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Inhibrx Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51M	1,475.14	-$581.60M	-$4.76	N/A
Inhibrx Biosciences	$1.30M	997.22	-$140.05M	-$8.88	N/A

CRISPR Therapeutics has a beta of 1.74, suggesting that its stock price is 74% more volatile than the broader market. Comparatively, Inhibrx Biosciences has a beta of 3.51, suggesting that its stock price is 251% more volatile than the broader market.

CRISPR Therapeutics currently has a consensus target price of $68.06, suggesting a potential upside of 27.09%. Inhibrx Biosciences has a consensus target price of $150.00, suggesting a potential upside of 69.74%. Given Inhibrx Biosciences' higher possible upside, analysts clearly believe Inhibrx Biosciences is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	1 Sell rating(s)	7 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.58
Inhibrx Biosciences	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33

In the previous week, Inhibrx Biosciences had 5 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 8 mentions for Inhibrx Biosciences and 3 mentions for CRISPR Therapeutics. CRISPR Therapeutics' average media sentiment score of 1.31 beat Inhibrx Biosciences' score of 0.08 indicating that CRISPR Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Inhibrx Biosciences	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

CRISPR Therapeutics and Inhibrx Biosciences tied by winning 8 of the 16 factors compared between the two stocks.

How does Inhibrx Biosciences compare to ACADIA Pharmaceuticals?

Inhibrx Biosciences (NASDAQ:INBX) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, earnings and risk.

82.5% of Inhibrx Biosciences shares are owned by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. 18.3% of Inhibrx Biosciences shares are owned by company insiders. Comparatively, 26.2% of ACADIA Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Inhibrx Biosciences presently has a consensus target price of $150.00, suggesting a potential upside of 69.74%. ACADIA Pharmaceuticals has a consensus target price of $33.69, suggesting a potential upside of 19.31%. Given Inhibrx Biosciences' higher probable upside, equities analysts plainly believe Inhibrx Biosciences is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibrx Biosciences	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33
ACADIA Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.82

Inhibrx Biosciences has a beta of 3.51, suggesting that its share price is 251% more volatile than the broader market. Comparatively, ACADIA Pharmaceuticals has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market.

In the previous week, ACADIA Pharmaceuticals had 9 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 17 mentions for ACADIA Pharmaceuticals and 8 mentions for Inhibrx Biosciences. ACADIA Pharmaceuticals' average media sentiment score of 0.94 beat Inhibrx Biosciences' score of 0.08 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inhibrx Biosciences	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
ACADIA Pharmaceuticals	7 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ACADIA Pharmaceuticals has higher revenue and earnings than Inhibrx Biosciences. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibrx Biosciences	$1.30M	997.22	-$140.05M	-$8.88	N/A
ACADIA Pharmaceuticals	$1.07B	4.54	$391M	$2.22	12.72

ACADIA Pharmaceuticals has a net margin of 33.42% compared to Inhibrx Biosciences' net margin of 0.00%. ACADIA Pharmaceuticals' return on equity of 9.03% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibrx Biosciences	N/A	-1,742.66%	-81.62%
ACADIA Pharmaceuticals	33.42%	9.03%	6.79%

Summary

ACADIA Pharmaceuticals beats Inhibrx Biosciences on 13 of the 17 factors compared between the two stocks.

How does Inhibrx Biosciences compare to Dyne Therapeutics?

Inhibrx Biosciences (NASDAQ:INBX) and Dyne Therapeutics (NASDAQ:DYN) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability, earnings and media sentiment.

82.5% of Inhibrx Biosciences shares are owned by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are owned by institutional investors. 18.3% of Inhibrx Biosciences shares are owned by company insiders. Comparatively, 9.5% of Dyne Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Inhibrx Biosciences had 6 more articles in the media than Dyne Therapeutics. MarketBeat recorded 8 mentions for Inhibrx Biosciences and 2 mentions for Dyne Therapeutics. Dyne Therapeutics' average media sentiment score of 1.03 beat Inhibrx Biosciences' score of 0.08 indicating that Dyne Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inhibrx Biosciences	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dyne Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Inhibrx Biosciences has a beta of 3.51, indicating that its stock price is 251% more volatile than the broader market. Comparatively, Dyne Therapeutics has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market.

Inhibrx Biosciences has higher revenue and earnings than Dyne Therapeutics. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibrx Biosciences	$1.30M	997.22	-$140.05M	-$8.88	N/A
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.33	N/A

Dyne Therapeutics' return on equity of -64.30% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibrx Biosciences	N/A	-1,742.66%	-81.62%
Dyne Therapeutics	N/A	-64.30%	-50.33%

Inhibrx Biosciences currently has a consensus target price of $150.00, suggesting a potential upside of 69.74%. Dyne Therapeutics has a consensus target price of $34.42, suggesting a potential upside of 33.92%. Given Inhibrx Biosciences' higher probable upside, equities research analysts clearly believe Inhibrx Biosciences is more favorable than Dyne Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibrx Biosciences	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.87

Summary

Dyne Therapeutics beats Inhibrx Biosciences on 9 of the 15 factors compared between the two stocks.

How does Inhibrx Biosciences compare to Celcuity?

Inhibrx Biosciences (NASDAQ:INBX) and Celcuity (NASDAQ:CELC) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, risk, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Celcuity's return on equity of -250.68% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibrx Biosciences	N/A	-1,742.66%	-81.62%
Celcuity	N/A	-250.68%	-50.23%

Inhibrx Biosciences has higher revenue and earnings than Celcuity. Celcuity is trading at a lower price-to-earnings ratio than Inhibrx Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibrx Biosciences	$1.30M	997.22	-$140.05M	-$8.88	N/A
Celcuity	N/A	N/A	-$177.04M	-$4.30	N/A

Inhibrx Biosciences has a beta of 3.51, suggesting that its share price is 251% more volatile than the broader market. Comparatively, Celcuity has a beta of 0.2, suggesting that its share price is 80% less volatile than the broader market.

Inhibrx Biosciences presently has a consensus price target of $150.00, indicating a potential upside of 69.74%. Celcuity has a consensus price target of $153.64, indicating a potential upside of 67.00%. Given Inhibrx Biosciences' higher probable upside, research analysts plainly believe Inhibrx Biosciences is more favorable than Celcuity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibrx Biosciences	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33
Celcuity	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

In the previous week, Celcuity had 14 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 22 mentions for Celcuity and 8 mentions for Inhibrx Biosciences. Celcuity's average media sentiment score of 0.47 beat Inhibrx Biosciences' score of 0.08 indicating that Celcuity is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inhibrx Biosciences	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Celcuity	7 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

82.5% of Inhibrx Biosciences shares are held by institutional investors. Comparatively, 63.3% of Celcuity shares are held by institutional investors. 18.3% of Inhibrx Biosciences shares are held by company insiders. Comparatively, 13.3% of Celcuity shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Inhibrx Biosciences beats Celcuity on 8 of the 15 factors compared between the two stocks.

How does Inhibrx Biosciences compare to Relay Therapeutics?

Relay Therapeutics (NASDAQ:RLAY) and Inhibrx Biosciences (NASDAQ:INBX) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, dividends and earnings.

Relay Therapeutics' return on equity of -42.27% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relay Therapeutics	N/A	-42.27%	-38.67%
Inhibrx Biosciences	N/A	-1,742.66%	-81.62%

Relay Therapeutics has a beta of 1.69, meaning that its stock price is 69% more volatile than the broader market. Comparatively, Inhibrx Biosciences has a beta of 3.51, meaning that its stock price is 251% more volatile than the broader market.

97.0% of Relay Therapeutics shares are owned by institutional investors. Comparatively, 82.5% of Inhibrx Biosciences shares are owned by institutional investors. 5.0% of Relay Therapeutics shares are owned by company insiders. Comparatively, 18.3% of Inhibrx Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Inhibrx Biosciences has lower revenue, but higher earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Inhibrx Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relay Therapeutics	$15.35M	283.53	-$276.48M	-$1.57	N/A
Inhibrx Biosciences	$1.30M	997.22	-$140.05M	-$8.88	N/A

Relay Therapeutics presently has a consensus price target of $25.83, indicating a potential upside of 30.08%. Inhibrx Biosciences has a consensus price target of $150.00, indicating a potential upside of 69.74%. Given Inhibrx Biosciences' higher probable upside, analysts clearly believe Inhibrx Biosciences is more favorable than Relay Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relay Therapeutics	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.86
Inhibrx Biosciences	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33

In the previous week, Relay Therapeutics had 2 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 10 mentions for Relay Therapeutics and 8 mentions for Inhibrx Biosciences. Relay Therapeutics' average media sentiment score of 0.75 beat Inhibrx Biosciences' score of 0.08 indicating that Relay Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relay Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Inhibrx Biosciences	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Relay Therapeutics beats Inhibrx Biosciences on 10 of the 16 factors compared between the two stocks.

Get Inhibrx Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INBX vs. The Competition

Export

Metric	Inhibrx Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.30B	$3.72B	$7.03B	$13.07B
Dividend Yield	N/A	3.69%	2.57%	10.64%
P/E Ratio	-9.95	10.83	271.54	25.40
Price / Sales	997.22	1,360.21	673.88	125.76
Price / Cash	N/A	101.42	75.70	53.27
Price / Book	160.67	16.78	12.92	6.21
Net Income	-$140.05M	-$13.32M	$3.45B	$347.71M
7 Day Performance	-0.33%	1.76%	1.16%	1.08%
1 Month Performance	-0.79%	2.86%	2.17%	1.87%
1 Year Performance	278.78%	54.10%	62.38%	20.79%

Inhibrx Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INBX Inhibrx Biosciences	2.0515 of 5 stars	$88.37 -8.9%	$150.00 +69.7%	+278.8%	$1.30B	$1.30M	N/A	166	News Coverage Earnings Report
CRSP CRISPR Therapeutics	3.672 of 5 stars	$54.07 +1.0%	$68.06 +25.9%	-10.3%	$5.17B	$3.51M	N/A	460	Positive News
ACAD ACADIA Pharmaceuticals	4.6569 of 5 stars	$29.41 +0.1%	$33.31 +13.2%	+11.5%	$5.06B	$1.07B	13.25	510	Analyst Forecast
DYN Dyne Therapeutics	3.7539 of 5 stars	$26.71 +0.8%	$34.42 +28.9%	+107.6%	$4.95B	N/A	N/A	100	Positive News
CELC Celcuity	3.4342 of 5 stars	$88.11 -3.0%	$155.18 +76.1%	+77.6%	$4.43B	N/A	N/A	40	Trending News Earnings Report Analyst Forecast Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INBX) was last updated on 8/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Inhibrx Biosciences (INBX) Competitors

INBX vs. CRSP, ACAD, DYN, CELC, and RLAY

How does Inhibrx Biosciences compare to CRISPR Therapeutics?

Summary

How does Inhibrx Biosciences compare to ACADIA Pharmaceuticals?

Summary

How does Inhibrx Biosciences compare to Dyne Therapeutics?

Summary

How does Inhibrx Biosciences compare to Celcuity?

Summary

How does Inhibrx Biosciences compare to Relay Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INBX vs. The Competition

Inhibrx Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Inhibrx Biosciences (INBX) Competitors

INBX vs. CRSP, ACAD, DYN, CELC, and RLAY

How does Inhibrx Biosciences compare to CRISPR Therapeutics?

Is CRSP or INBX more profitable?

Do insiders & institutionals have more ownership in CRSP or INBX?

Which has higher earnings & valuation, CRSP or INBX?

Which has more risk & volatility, CRSP or INBX?

Do analysts rate CRSP or INBX?

Does the media favor CRSP or INBX?

Summary

How does Inhibrx Biosciences compare to ACADIA Pharmaceuticals?

Do institutionals and insiders have more ownership in INBX or ACAD?

Do analysts prefer INBX or ACAD?

Which has more risk & volatility, INBX or ACAD?

Does the media refer more to INBX or ACAD?

Which has better earnings & valuation, INBX or ACAD?

Is INBX or ACAD more profitable?

Summary

How does Inhibrx Biosciences compare to Dyne Therapeutics?

Do institutionals & insiders hold more shares of INBX or DYN?

Does the media favor INBX or DYN?

Which has more volatility & risk, INBX or DYN?

Which has preferable valuation & earnings, INBX or DYN?

Is INBX or DYN more profitable?

Do analysts rate INBX or DYN?

Summary

How does Inhibrx Biosciences compare to Celcuity?

Is INBX or CELC more profitable?

Which has higher valuation & earnings, INBX or CELC?

Which has more risk & volatility, INBX or CELC?

Do analysts prefer INBX or CELC?

Does the media favor INBX or CELC?

Do institutionals and insiders believe in INBX or CELC?

Summary

How does Inhibrx Biosciences compare to Relay Therapeutics?

Is RLAY or INBX more profitable?

Which has more volatility & risk, RLAY or INBX?

Do insiders and institutionals believe in RLAY or INBX?

Which has better earnings and valuation, RLAY or INBX?

Do analysts prefer RLAY or INBX?

Does the media refer more to RLAY or INBX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INBX vs. The Competition

Inhibrx Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools